)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Fagron
Fagron (FAGR) investor relations material
Fagron Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary8 Oct, 2026
Executive summary
Q3 revenue was €281.260m, up 23.2% reported and 19.5% at CER; organic growth at CER was 3.4%, led regionally by EMEA and Latin America.
9M revenue reached €833.743m, up 18.4% reported and 18.1% at CER, with 3.2% organic growth at CER.
FY 2026 revenue and adjusted EBITDA margin guidance was confirmed; stabilized IV bag supply is expected to support progressive Compounding Services recovery in Q4.
All announced acquisitions are closed and integration is on track, with full contribution expected in 2027.
Financial highlights
Q3 category revenue: Essentials €133.646m, up 47.4%; Brands €42.886m, up 13.3%; Compounding Services €104.727m, up 5.0%.
9M revenue was €833.743m versus €704.353m, up 18.4% reported and 18.1% at CER; organic growth at CER was 3.2%.
Management cited 6% year-to-date growth when normalizing for GLP-1 effects.
Injeplast revenue was described as a low-double-digit amount; its acquisition multiple was 6x–9x EBITDA, with margins in line with the group average.
Outlook and guidance
FY 2026 revenue guidance remains €1,125m–€1,150m, with adjusted EBITDA margin of 19.5%–20.0%.
FY 2026 CapEx is expected to be ~3.5% of revenue, excluding one-off projects; guidance assumes no significant changes in market conditions.
IV bag supply has stabilized; Compounding Services volumes are expected to recover progressively through Q4, with the business expected back at its Q1 2026 level during Q1 2027.
The pace of U.S. Compounding Services recovery depends on customer sales cycles and order commitments; 2027 is expected to be on track, supported by capacity and demand.
Medium-term objectives remain unchanged, and North America–Pacific is viewed as at an inflection point.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Fagron
- Revenue up 16% to €552.5M, EBITDA €107.1M, net profit €46.5M, six acquisitions completed.FAGR
H1 2026 - Q1 2026 revenue up 10.3% to €263.4m, led by Latin America and robust M&A integration.FAGRQ1 2026 TU
- Revenue up 9.2%, margin and cash flow gains, and M&A drive positive 2026 outlook.FAGRH2 2025
- Q3 2025 revenue up 6.4%, organic growth 8.5%, and FY 2025 outlook confirmed at €930–€950 million.FAGRQ3 2025 TU
- Double-digit revenue and profit growth, global expansion, and major capacity investment.FAGRH1 2025
- Q3 2024 revenue up 12.1% with strong organic growth and three strategic acquisitions.FAGRQ3 2024
- Double-digit growth, margin gains, and upgraded outlook driven by North American strength.FAGRH1 2024
- Targets high single- to low double-digit organic growth and ~21% EBITDA margin by 2027.FAGRCMD 2025
- Double-digit growth, margin expansion, and six acquisitions drive strong FY 2024 results.FAGRH2 2024
Next Fagron earnings date
Q4 202611 Feb, 2027
Fagron
Next Fagron earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Fagron NV is a multinational company that operates within the healthcare sector, specializing in the provision of products and services for pharmaceutical compounding. It supplies a wide range of products, including raw materials, flammable products, extracts and tinctures, anesthetics, syrups, ointment bases, medispend, triturations, suspension media, phyto pharmaflore, capsicards systems, and consumables. These offerings support the customized preparation of medications to meet specific patient needs, catering to various applications such as allergy, skin care, and hemorrhoids. The company's operations span across Europe, the United States, Brazil, and Argentina, divided into four main segments: Fagron Specialty Pharma Services, Fagron Trademarks, Fagron Essentials, and HL Technology. The company is headquartered in Nazareth, Belgium, and its shares are listed on the Euronext Brussels.